Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (NASDAQ: EXAS) is frequently in the news as a leading provider of cancer screening and diagnostic tests. Company announcements highlight developments across stool-based colorectal cancer screening, multi-cancer early detection, liver cancer surveillance, and precision oncology genomics. News coverage often reflects new clinical data, product launches, collaborations, and corporate transactions that shape the company’s role in cancer diagnostics.
Investors and clinicians following EXAS news can expect updates on the performance and adoption of the Cologuard and Cologuard Plus colorectal cancer screening tests, including real‑world adherence data and modeling studies that examine benefit‑to‑burden trade‑offs. Exact Sciences also reports on progress with its Cancerguard multi‑cancer early detection blood test, including study results from large prospective trials designed to support broader clinical use.
Another recurring theme in Exact Sciences news is the expansion of its precision oncology and surveillance portfolio. Releases describe pivotal and prospective studies of the Oncoguard Liver blood test for hepatocellular carcinoma surveillance, the Oncodetect molecular residual disease test in high‑risk breast cancer and other solid tumors, and the OncoExTra comprehensive genomic profiling assay for advanced cancers. These updates often come from major scientific meetings and include details on sensitivity, specificity, and prognostic performance.
Corporate and financial news items for EXAS include quarterly earnings releases, updated revenue and adjusted EBITDA guidance, participation in investor conferences, and strategic agreements such as the collaboration and license arrangement with Freenome for blood‑based colorectal cancer screening tests. A notable development disclosed in both press releases and SEC filings is the definitive agreement under which Abbott Laboratories plans to acquire Exact Sciences, subject to stockholder and regulatory approvals and other customary conditions.
This news page aggregates such announcements, offering a single place to review Exact Sciences’ latest clinical, product, financial, and transaction-related updates over time.
Exact Sciences Corp. (Nasdaq: EXAS) announced participation in several upcoming virtual investor conferences. Management will engage in fireside chats at notable events including the William Blair 41st Annual Growth Stock Conference on June 1, Jefferies Virtual Healthcare Conference on June 2, and Goldman Sachs 42nd Annual Global Healthcare Conference on June 9. Another chat will occur at the Nephron Research Liquid Biopsy Innovation Symposium on June 16. Investors can access the webcasts in the investor relations section of Exact Sciences' website.
Exact Sciences Corp. (NASDAQ: EXAS) presented significant findings at the 2021 Digestive Disease Week, demonstrating that Cologuard is cost-effective in reducing colorectal cancer (CRC) incidence and mortality, outperforming traditional tests like FIT and FOBT. Data from a New Hampshire study indicated Cologuard's higher efficacy in predicting neoplasia owing to better detection of serrated polyps. Despite rising colorectal cancer rates among younger adults, 44 million average-risk individuals in the U.S. remain unscreened.
Exact Sciences Corp. (NASDAQ: EXAS) announced the presentation of new cancer diagnostics data at the 2021 ASCO Annual Meeting, scheduled for June 4-8. The company will showcase findings that support the Oncotype DX® tests and their role in personalized treatment decisions. Additionally, research from Thrive highlights the importance of a blood-based multi-cancer screening test in clinical care. The data presentations affirm Exact Sciences' commitment to enhancing cancer detection and treatment.
Exact Sciences (NASDAQ: EXAS) celebrates the USPSTF's recommendation for colorectal cancer screening to begin at age 45. Cologuard, their FDA-approved stool DNA test, is endorsed for average-risk patients aged 45-75. The recommendation addresses the increase in colorectal cancer incidence among younger adults. With 44 million eligible adults, Cologuard's inclusion in guidelines aims to enhance screening rates. It has successfully detected 92% of colorectal cancers in studies. This change could elevate healthcare provider discussions on screening options and expand Cologuard's market impact.
Exact Sciences Corp. reported first-quarter 2021 revenue of $402.1 million, up 16% from $347.8 million in Q1 2020. Screening revenue grew by 10% to $240.3 million, while Precision Oncology revenue increased by 1% to $129.4 million. COVID-19 testing contributed $32.3 million. The gross margin was 68%, with a non-GAAP gross margin of 73%. The income tax benefit was $242.8 million, leading to a net loss of $31.2 million, improved from $134.6 million in the prior year. The company forecasts full-year revenue between $1,690 million and $1,735 million.
Exact Sciences Corp. (Nasdaq: EXAS) announced management will participate in two upcoming investor conferences in May 2021. The BofA Securities Virtual Healthcare Conference will feature a fireside chat on May 12 at 1:15 p.m. EDT, while the UBS Global Healthcare Virtual Conference will take place on May 25 at 4:00 p.m. EDT. Investors can access the webcasts through the investor relations section of the Exact Sciences website. Exact Sciences focuses on cancer screening and diagnostic tests, aiming to enhance patient care and combat deadly cancers.
Exact Sciences (NASDAQ: EXAS) announced that Cologuard is the most cost-effective colorectal cancer screening option for the Alaska Native population, according to a study published in Mayo Clinic Proceedings. The study demonstrates that Cologuard, a non-invasive stool DNA test, produces the highest number of quality-adjusted life years (QALYs) and significantly reduces colorectal cancer incidence compared to colonoscopy and fecal immunochemical test (FIT). With challenges in screening adherence, Cologuard’s home-use capability presents a promising solution for increasing screening rates.
Exact Sciences Corp. (NASDAQ: EXAS) announced the successful acquisition of Ashion Analytics, enhancing its capabilities in precision oncology. This acquisition includes a CLIA-certified lab and advanced genomic testing options, specifically the GEM ExTra® test. The collaboration with The Translational Genomics Research Institute (TGen) aims to improve advanced cancer diagnostics. This strategic move is projected to bolster patient care and extend Exact Sciences' market leadership in cancer treatment.
Exact Sciences Corp. (Nasdaq: EXAS) will release its first quarter 2021 financial results on May 4, 2021, after the U.S. markets close. Following this, a webcast and conference call will be held at 5 p.m. EDT to discuss the results and business developments. The company focuses on cancer screening and diagnostics, leveraging successful products like Cologuard and Oncotype DX. Exact Sciences aims to enhance patient care through innovative solutions and continued investment in its product pipeline.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in two upcoming virtual investor conferences. The company will hold a fireside chat at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 11:50 a.m. EST, and at the Barclays Global Healthcare Conference on March 9, 2021, at 9:10 a.m. EST.
Investors can access the webcasts via the investor relations section of Exact Sciences' website. The company continues to focus on cancer screening and diagnostic tests to improve patient care.